Ozempic and Wegovy may be doing something few people expected: weakening the slide from impulse to violence.
Quick Take
- Rutgers researchers report a weaker link between impulsivity and violent behavior among current GLP-1 users.[16]
- The study used survey data from 7,521 U.S. adults and focused on 821 people who had ever used a GLP-1 drug.[1]
- The result is an association, not proof that the drugs cause less violence.[1][16]
- The finding fits a broader pattern: GLP-1 drugs seem to affect reward, craving, and self-control.[8][9][19][21]
A Surprising Signal From a Weight Loss Drug
The headline is eye-catching for a reason. Ozempic and Wegovy are best known for weight loss and blood sugar control, not for behavior. Yet Rutgers researchers reported that current GLP-1 users showed a much weaker link between impulsivity and violent behavior than former users.[16] That does not mean the drugs stop violence. It does mean the study found a pattern that begs for a deeper look.
The basic setup matters. Researchers analyzed survey data from a nationally representative U.S. sample of 7,521 adults and then focused their main analysis on 821 people who had ever used a GLP-1 medication.[1][16] Across the full sample, impulsivity and alcohol use were tied to violent behavior. But among current users, those ties were less strong.[1] That is the kind of result that can hint at a real drug effect, while still leaving the door open to other explanations.
What the Study Actually Found
The reported numbers are striking. The link between impulsivity and violent behavior was about 62% weaker among current users than among former users.[1][16] The alcohol link was also weaker, by about 52%, though that result was less stable across sensitivity checks.[1][16] Rutgers described the work as observational and cross-sectional, which means the researchers looked at one snapshot in time rather than tracking people before and after treatment.[1][16]
That distinction is the whole ballgame. A cross-sectional study can show that two things move together. It cannot prove that one caused the other.[1][16] Current GLP-1 users could differ from former users in many ways that the survey did not fully capture. They may differ in health status, treatment history, mental health, substance use, or other factors that shape both medication use and violent behavior. Without the full paper in hand, those questions stay open.
Why Researchers Think the Signal Is Plausible
The interest here is not random. GLP-1 drugs already have a known effect on appetite and satiety, and research from Rutgers has discussed GLP-1 signaling in reward-related behavior.[9][15][19] Other recent work also links GLP-1 use to lower odds of substance use disorders, again pointing toward reward and craving pathways.[21] If a drug can blunt the urge to overeat or misuse substances, it is not absurd to ask whether it may also soften the jump from impulse to action.
A Rutgers study suggests GLP-1 drugs such as Ozempic and Wegovy may weaken the link between impulsive tendencies and violent behavior. The surprising finding hints that these medications could affect how people act on impulses, though researchers stress thhttps://t.co/K2TJUYBY9e
— Michael W. Deem (@Michael_W_Deem) June 17, 2026
Still, plausible does not mean proven. The Rutgers team itself said the finding should be treated as a first step, not a final answer.[16] That caution is important because the claim touches a nerve in public debate. People already have strong views about Ozempic and Wegovy, from health hopes to fears about misuse and side effects.[8] When a drug is already a cultural lightning rod, even a modest behavioral signal can get blown up into a bigger story than the data can support.
What Would Count as Real Proof
The next test should be simple in principle and hard in practice. Researchers need longitudinal data that track people before and after GLP-1 treatment starts.[1][16] They need objective outcomes, not just self-report. Arrest records, emergency room visits, police calls, or clinical incident reports would be stronger than survey answers alone. They also need careful adjustment for psychiatric diagnosis, substance use, and criminal history. Without that work, the safest reading is still cautious.
That caution does not make the finding worthless. It makes it honest. A drug class built for metabolism may turn out to influence behavior in ways scientists did not expect. Or this may be a temporary signal shaped by who gets the drugs and who stays on them. Either way, the Rutgers result has opened a strange and important question: when a medicine changes craving, does it also change the path from urge to harm?
Sources:
[1] Web – Ozempic and Wegovy linked to surprising drop in violent behavior
[8] Web – Can weight loss jabs reduce behaviours linked to violent crime?
[9] Web – Is There a Risk for Semaglutide Misuse? Focus on the Food … – PMC
[15] Web – Clinical reports suggest diabetes and obesity drugs like Ozempic …
[16] Web – Body image and interest in GLP-1 weight loss medications
[19] Web – Researchers link use of GLP-1 medications to lower risk of violence
[21] Web – Can use of popular weight loss medications reduce behaviors linked …
